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ABSTRACT
OBJECTIVE: In recent decades there has been an increase in the use of antidepressants (AD) and 
a decrease in the use of benzodiazepines (BDZ). Prevalence, cumulative incidence, and factors 
associated with the incidence of AD and BDZ use in a Brazilian population were estimated in 
this article.
METHODS: Data were collected with a self-administered questionnaire in a cohort of employees 
from a university in Rio de Janeiro. The prevalence of the use of AD and BDZ was calculated for 
1999 (4,030), 2001 (3,574), 2006-07 (3,058), and 2012 (2,933). The cumulative incidences of the 
use of AD and BDZ between 1999 and 2007 were estimated by the Poisson models with robust 
variance estimates.
RESULTS: In 1999, the prevalence of the use of AD and BDZ were 1.4% (95%CI: 1.1–1.8) and 4.7% 
(95%CI: 4.1–5.4), respectively; in 2012, they were 5.4% (95%CI: 5.5–6.2) and 6.8% (95%CI: 6.0–7.8). 
The incidence of use, between 1999 and 2007, was 4.9% (95%CI: 4.2–5.7) for AD and 8.3% 
(95%CI: 7.3–9.3) for BDZ. The incidences of AD and BDZ use were higher among women and 
participants with a positive General Health Questionnaire.
CONCLUSION: In this population, the increase in the use of AD was not accompanied by 
a decrease in the use of BDZ, showing the prescriptions for psychotropic medication do not 
follow the currently recommended guidelines for treatment of common mental health disorders.
DESCRIPTORS: Benzodiazepines, administration & dosage. Antidepressive Agents, 
administration & dosage. Drug Utilization, trends. Cohort Studies.
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INTRODUCTION
Antidepressants (AD) and benzodiazepines (BDZ) are the most used psychotropic 
medications. The first AD was introduced in the 1950s and presented important side effects 
and contraindications, while BDZ showed fewer side effects and were considered to be 
safer, resulting in their more frequent prescription by psychiatrists and non-psychiatrists 
alike. With the introduction of fluoxetine, a selective serotonin reuptake inhibitors (SSRI) in 
the 1980s with fewer side effects, the AD use increased more than the observed for BDZ1,2. 
International guidelines recommend the use of BDZ should be restricted to patients with 
major depression disorders associated with anxiety and/or insomnia, and only if the AD 
did not provide an adequate treatment2,3.
In 1988, in the United States (US), 9.7% of patients with a depression diagnosis received 
a prescription for the SSRI fluoxetine. This proportion gradually rose to 21% (1989), 46% 
(1993), and 69% (2001). In parallel, there was a decrease in the use of BDZ for depression 
treatment: in 1987, 21% of individuals used BDZ for this purpose, but in 2001 the proportion 
was only 7.5%1.
There is significant variation in the prevalence of use of AD and BDZ in the general population 
among countries, for example 2.9% (AD) and 3.8% (BDZ) in Chile in 1996–984; 4.7% (AD) and 
11.4% (BDZ) in Spain in 2001–025; and 7.2% (AD) and 12.3% (BDZ) in Belgium in 2001–026. 
A study conducted in 2000 in six European countries (Belgium, France, Germany, Italy, 
Netherlands and Spain), estimated 3.7% annual prevalence for AD and 9.8% for BDZ7.
In Brazil, a study in 1988 among 1,459 residents in Rio de Janeiro found a 5.2% prevalence for 
the use of psychotropic medicine in the previous month, 85% being BDZ8. Around 20 years 
later, in another study in Rio9, the most used type of psychotropic medicines in the previous 
month was the AD, with 2.8%, and the prevalence of BDZ use was 1.6%. Several studies 
have been conducted in São Paulo. In 1990, among 1,742 individuals, only five had used 
AD in the previous 12 months, compared with the 140 that had used BDZ, a prevalence of 
8%10. Later (2007), one study estimated similar prevalence of BDZ (3.7%) and AD (3.5%) use 
in the previous 12 months11, and in another one the prevalence of AD use in the previous 
30 days was 3.1%, and BDZ use was 2.7%12. Studies point to greater use of psychotropic 
medicine by women, older adults, those with a higher income and education (especially 
in the AD case), the unemployed, and people who are separated or divorced2,9,11–14. Some 
findings are inconsistent as some studies report, for example, a higher prevalence among 
less educated individuals2,8.
The objective of this study is to investigate the prevalence and cumulative incidence of AD 
and BDZ among Brazilian adults and factors associated with the use of these medicines. 
This study hypothesizes that the use of AD has been increasing since the year 2000 while 
the use of BDZ has been decreasing.
METHODS
Study design
A concurrent cohort study with data from the Pró-Saúde Study, a longitudinal study of 
university civil servants in Rio de Janeiro15.
The wave 1 of the study (baseline) occurred in 1999, with 4,030 participants (91% of those 
eligible); wave 2 occurred in 2001–2 (3,574 individuals, 83% of those eligible); wave 3 occurred 
in 2006-7, with 3,058 individuals (76% of those eligible); wave 4 occurred in 2012, with 
2,933 individuals (58% of those eligible)15.
The ethics committee of the Universidade Estadual do Rio de Janeiro approved the research 
protocol; all subjects signed an informed consent form.
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Variables
The variables used in the study were obtained with a self-administered questionnaire 
applied during wave 1 (1999):
•  Sociodemographic (sex, age, marital state, self-reported race/skin color, education level, 
and equivalent income compared with minimum wage at the time).
• Use of alcohol. This variable was assessed by three questions: i. “Did you consume any 
type of alcoholic drink in the last two weeks?” ii. “How many days did you consume any 
type of alcoholic drink in the last two weeks?” iii. “How many doses did you consume in the 
days you drank in the last two weeks?”
• Self-reported health assessment (general health condition and current health condition).
• Sleep problems (difficulty in initiating sleep and waking up frequently at night).
• Tiredness for no apparent reason.
• Mental health was assessed with the Brazilian version of the General Health Questionnaire 
– GHQ-12 (validated by a structured psychiatric interview)16 during waves 1, 2, and 
3 of the study. The GHQ-12 scores were dichotomized, using scores from 3 or more as 
indicative of common mental disorder (CMD).
• The use of psychotropic drugs was assessed with the construction of a dichotomous 
variable (no/yes) based on a question referring to medicine use: “During the past two 
weeks, have you used any medicine? If the answer is yes, which medicine have you used in 
the past two weeks?”. During waves 3 and 4, the information about medicine use regarded 
the previous seven days.
The participants were classified as AD or BDZ users if reported (i) the name of the substance 
or (ii) the pharmacological class. If the name of the medicine was not reported, the 
Anatomical Therapeutic Chemical (ATC) classification was used17.
Analysis
A descriptive analysis of the study population was performed with measures estimations 
of central tendency and dispersion for the continuous variables and frequency distribution 
for the categorical variables. Prevalence and 95% confidence interval (CI) were estimated 
for the use of AD and BDZ.
Then a fixed cohort with individuals who did not use AD or BDZ during wave 1 was 
assembled and observed until wave 3, thus providing eight years of follow-up. Cumulative 
incidences of AD and BDZ were estimated in both phases following wave 1 of the study. 
Wave 4 was excluded from the follow-up analysis due to many study participants who 
quit the follow-up. In an exploratory data analysis, incidences were estimated and 
stratified by sociodemographic, general, and mental health variables. The initial choice 
of variables among the ones collected in the original study considered the relationship 
of the variables with the use of AD and BDZ present in the literature. The associations 
were considered statistically significant if p-value ≤ 0.05, and of borderline statistical 
significance if between 0.06 and 0.10.
To estimate the cumulative incidence ratio (relative risk) the Poisson regression 
models with robust variance estimates were adjusted, having as a dependent variable 
the incidence of AD and BDZ use. Initially, the models were adjusted with only one 
independent variable at a time. Variables associated with p-values ≤ 0.20 were selected 
for subsequent assessment in the multivariate models, with their inclusion one by one; 
those associated with p-values > 0.10 were kept in the model.
The analysis was performed using the statistical software Stata version 12.
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RESULTS
Population characteristics during wave 1 (baseline)
The overall sample in wave 1 contained 4,030 individuals. Most of them were female (55%), 
ranging from 35 to 44 years of age (43%). Most participants were married/cohabiting (60%), 
self-reported as being white (52%), who completed higher education (27%), and worked at 
the university hospital (49%). Two-thirds of the individuals had an income greater than six 
times the minimum wage. More than half the individuals (56%) reported having private 
health insurance (Table 1).
Almost half the participants classified their health as good, and two-thirds considered their 
current health condition to be the same as 12 months before. Mental health assessment 
with the GHQ-12 showed 31% met the criteria for CMD. Two-thirds of the individuals said 
they never or rarely had trouble falling asleep. Also they never or rarely woke up during 
the sleep cycle. More than half the participants (56%) never or rarely declared tiredness for 
no reason (Table 1).
Prevalence of antidepressant and benzodiazepine use
The prevalence of AD and BDZ use was higher among women. The greatest difference was in AD 
use, with women presenting a prevalence of approximately four times higher than men (Table 1).
Overall, the prevalence of AD use increased with age. As for the BDZ, there was an increase 
in usage by people between 45 and 54 years old. The prevalence of both AD and BDZ use 
was lower in married individuals, and for BDZ it was also lower in the single group (Table 1).
The prevalence of AD and BDZ use lacked distinctions by race/color, education level, income, and 
possession of private health insurance. Regarding the workplace, the only difference in prevalence 
was in BDZ use, which was 35% higher among participants at the university hospital (Table 1).
Increased use of AD and BDZ was noticed when the individual had a worse health perception. 
Among individuals with CMD, the prevalence of AD and BDZ use was close to four times 
higher. There was an increasing gradient of AD and BDZ use with the intensity of sleep 
complaints or with tiredness for no apparent reason (Table 1).
In 1999, the prevalence of AD use in the 15 previous days was reported by 1.4% of participants 
(95%CI: 1.1–1.8); in 2012, even over a smaller span (the previous seven days), the prevalence 
was 5.4% (95%CI: 4.6–6.2). As for the prevalence of BDZ, there was a progressive, although 
discreet, increase in use with an apparent tendency to stability: being 4.7% (95%CI: 4.1–5.4) 
in 1999 and 6.8% (95%CI: 6.0–7.8) in 2012 (Figure 1).
In 1999, 58 individuals reported using AD in the previous two weeks. Tricyclic antidepressants 
(TCA), which represented in 1999 60.3% of the used AD, decreased to 15.2% in 2012. In 
contrast, SSRI boosted the increase in AD use, from 29.3% in 1999 to 67.6% in 2012, being 
primarily responsible for this increase. In parallel, there was a significant decrease in the 
use of bromazepam, from 43.7% in 1999 to 12.0% in 2012 (Table 2).
Incidence of antidepressant and benzodiazepine use
There were increases in AD and BDZ use throughout the study period. The incidence of AD 
in 2001 was 1.5%, and 3.4% for BDZ. For the years of 2006-7, the cumulative incidence of 
eight years after wave 1 (baseline) were 3.6% for AD and 5.0% for BDZ.
The incident cases in both waves after the baseline totaled 150 individuals (4.9%) for AD and 
243 (8.3%) for BDZ. The incidence among women was 3.4 times higher for AD and twice as 
high for BDZ than among men. Individuals aged 55 years or older used AD the least (1.7%); 
the opposite was found in the incidence of BDZ (13.3%). Widowers were those who most 
started using AD (7.4%) and BDZ (22.2%) in the follow-up period. (Table 3).
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Table 1. Sociodemographic characteristics, self-reported health conditions, and prevalence of antidepressants and benzodiazepines use at 
the baseline (1999). Pró-Saúde Study, Brazil.
Baseline (4,030) 
N (%)
Prevalence of AD % 
(95%CI)
p-value
Prevalence of BDZ % 
(95%CI)
p-value
Total  1.4 (1.1–1.8) 4.7 (4.0–5.4)  
Sex   
 Men 1,792 (44.5) 0.5 (0.2–0.9)
< 0.001
2.8 (2.1–3.6)
< 0.001
 Women 2,238 (55.5) 2.1 (1.5–2.7) 6.2 (5.2–7.2)
Age
 22–34 1,124 (27.9) 1.3 (0.7–2.0)
0.922
2.2 (1.4–3.1)
< 0.001
 35–44 1,740 (43.1) 1.4 (0.8–1.9) 5.0 (4.0–6.1)
 45–54 885 (22.0) 1.6 (0.7–2.4) 7.0 (5.3–8.7)
 55 or more 281 (7.0) 1.8 (0.2–3.3) 5.3 (2.7–8.0)
Marital status      
 Married or living together 2,397 (59.5) 1.0 (0.6–1.4)
0.06
4.1 (3.3–4.9)
< 0.001
 Separated or divorced 611 (15.0) 2.1 (1.0–3.3) 8.3 (6.1–10.5)
 Widower 116 (3.0) 2.6 (0.0–5.5) 6.9 (2.3–11.5)
 Single 805 (20.0) 2.0 (1.0–2.9) 3.5 (2.2–4.7)
 No information 101 (2.5) – –
Race   
 Black 626 (15.5) 1.4 (0.5–2.4)
0.811
4.9 (3.2–6.6)
0.576
 Brown 1,171 (29.1) 1.4 (0.8–2.1) 4.4 (3.2–5.6)
 White 2,082 (51.7) 1.5 (1.0–2.1) 5.0 (4.0–5.9)
 Asian 60 (1.5) – 3.3 (–1.2–7.9)
 Indigenous 41 (1.0) – –
 No information 50 (1.2) – –
Education level      
 Some elementary school 276 (6.8) 1.1 (–0.1–2.3)
0.951
5.1 (2.5–7.7)
0.609
 Elementary school 305 (7.6) 1.6 (0.2–3.1) 3.9 (1.7–6.1)
 Some high school 365 (9.0) 1.4 (0.2–2.6) 6.6 (4.0–9.1)
 High school 870 (21.6) 1.6 (0.8–2.4) 4.8 (3.4–6.2)
 Some college 560 (14.0) 1.2 (0.3–2.2) 3.7 (2.2–5.3)
 College 1,084 (27.0) 1.3 (0.6–2.0) 4.7 (3.4–6.0)
 Graduate 523 (13.0) 1.9 (0.7–3.1) 4.6 (2.8–6.4)
 No information 47 (1.0) –  –  
Workplace
 UERJ1 Campus 2,053 (51.0) 1.2 (0.7–1.7)
0.229
4.0 (3.2–4.9)
0.04
 HUPE2 Hospital 1,977 (49.0) 1.7 (1.1–2.2) 5.4 (4.4–6.4)
Income (equal to number of minimum wages)     
 Up to 3 329 (8.7) 1.2 (0.02–2.4)
0.6
5.7 (3.2–8.3)
0.619 3 to 6 967 (25.5) 1.1 (0.5–1.8) 4.4 (3.1–5.7)
 > 6 2,490 (65.8) 1.6 (1.1–2.0) 4.7 (3.9–5.6)
Health insurance users     
 Yes 2,266 (56.2) 1.5 (0.9–2.0)
0.638
4.9 (4.0–5.9)
0.446 No 1,739 (43.1) 1.3 (0.8–1.8) 4.4 (3.4–5.4)
 No information 25 (0.6) – –
Alcohol consumption
 Yes 2,148 (53.3) 1.1 (0.6–1.5)
0.03
3.9 (3.1–4.8)
0.01
 No 1,751 (43.5) 1.9 (1.2–2.5) 5.7 (4.6–6.8)
 No information 131 (3.2) – –
Frequency of alcohol consumption (2 weeks)
 Every day 84 (2.1) 1.2 (0.0–3.5)
0.73
5.9 (0.8–11.0)
0.76
 10 to 13 days 77 (1.9) – 2.6 (0.0–6.2)
 6 to 9 days 172 (4.3) 0.6 (0.0–1.7) 3.5 (0.7–6.2)
 2 to 5 days 1.098 (27.2) 1.0 (0.4–1.6) 4.2 (3.0–5.4)
 1 single day 708 (17.6) 1.4 (0.5–2.3) 3.5 (2.2–4.9)
(Continue)
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Baseline (4,030) 
N (%)
Prevalence of AD % 
(95%CI)
p-value
Prevalence of BDZ % 
(95%CI)
p-value
Amount of alcohol consumed per day (2 weeks)
 1 standard unit 631 (15.7) 1.1 (0.3–1.9)
0.98
3.2 (1.8–4.5)
0.3
 2 to 4 standard unit 902 (22.4) 1.1 (0.4–1.8) 4.1 (2.8–5.4)
 5 to 7 standard unit 311 (7.7) 1.0 (0.0–2.0) 3.2 (1.2–5.2)
 8 a 10 standard unit 141 (3.5) 1.4 (0.0–3.4) 5.0 (1.4–8.6)
 More than 10 standard unit 131 (3.2) 0.8 (0.0–2.3) 6.9 (2.5–11.2)
Health condition      
 Very good 1,132 (28.1) 0.4 (0.05–0.8)
< 0.001
1.8 (1.0–2.5)
< 0.001
 Good 2,131 (52.9) 1.2 (0.7–1.6) 4.3 (3.4–5.1)
 Regular 683 (16.9) 3.2 (2.0–4.5) 9.9 (7.7–12.2)
 Bad 63 (1.6) 9.5 (2.2–16.8) 14.3 (5.6–23.0)
 No information 21 (0.5) – –
Current health condition      
 Better than 12 months ago 784 (19.5) 2.4 (1.3–3.5)
< 0.001
5.3 (3.8–6.9)
< 0.001
 Same as 12 months ago 2,721 (67.5) 0.9 (0.5–1.2) 3.3 (2.6–4.0)
 Worse than 12 months ago 501 (12.4) 3.0 (1.5–4.5) 11.4 (8.6–14.2)
 No information 24 (0.6) – –
GHQ-12 (positive ≥ 3)      
 Negative 2,740 (68.0) 0.7 (0.4–1.0)
< 0.001
2.3 (1.8–2.9)
< 0.001 Positive 1,233 (30.6) 3.1 (2.1–4.0) 10.1 (8.4–11.8)
 No information  57 (1.4) – –
Difficulty falling asleep     
 Always 178 (4.4) 5.0 (1.8–8.3)
< 0.001
23.6 (17.3–29.8)
< 0.001
 Almost Always 297 (7.4) 5.5 (2.5–7.5) 14.5 (10.5–18.5)
 Sometimes 933 (23.1) 1.7 (0.9–2.5) 5.5 (4.0–7.0)
 Rarely 887 (22.0) 0.8 (0.2–1.4) 2.7 (1.6–3.8)
 Never 1,699 (42.2) 0.6 (0.2–1.0) 1.5 (0.9–2.1)
 No information 36 (0.9) – –
Wake up during sleep cycle      
 Always 139 (3.5) 4.3 (0.9–7.7)
< 0.001
23.7 (16.6–30.8)
< 0.001
 Almost always 320 (7.9) 3.7 (1.7–5.8) 11.2 (7.8–14.7)
 Sometimes 902 (22.4) 2.0 (1.1–2.9) 6.8 (5.1–8.4)
 Rarely 915 (22.7) 1.5 (0.7–2.3) 3.7 (2.5–4.9)
 Never 1,723 (42.7) 0.5 (0.1–0.8) 1.4 (0.8–1.9)
 No information 31 (0.8) – –
Tiredness for no apparent reason     
 Always 191 (4.7) 4.2 (1.3–7.0)
< 0.001
16.2 (11.0–21.5)
< 0.001
 Almost always 423 (10.5) 4.5 (2.5–6.5) 10.2 (7.3–13.0)
 Sometimes 1,107 (27.5) 1.5 (0.8–2.3) 5.5 (4.2–6.8)
 Rarely 765 (19.0) 1.0 (0.3–1.8) 2.9 (1.7–4.1)
 Never 1,504 (37.3) 0.3 (0.0–0.6) 1.9 (1.2–2.6)
 No information 40 (1.0) – –
1 Universidade Estadual do Rio de Janeiro
2 Hospital University Pedro Ernesto
Table 1. Sociodemographic characteristics, self-reported health conditions, and prevalence of antidepressants and benzodiazepines use at 
the baseline (1999). Pró-Saúde Study, Brazil. (Continuation)
7Antidepressants and Benzodiazepines Use Alcantara GC et al.
http://doi.org/10.11606/s1518-8787.2020054001887
There was greater AD use among better educated individuals, whereas BDZ use was more 
uniform among the educational categories. The incidences of AD and BDZ use were 39% 
higher among individuals who worked at the university hospital. The incidence of AD and 
BDZ use was higher among those who reported having poor or regular health. Individuals 
who declared their health to be worse than it was 12 months before were shown to have 
higher incidence, although in BDZ cases this was also observed for those who declared 
their health to be better than before. The incidence of AD and BDZ use practically doubled 
among individuals with CMD. Most participants who started to use AD and BDZ after 
wave 1 reported sleep complaints and tiredness for no reason (Table 3).
The incidence of AD use among BDZ users and non-users was investigated at the baseline 
and was three times higher among individuals who used BDZ (12.2%) compared with those 
who did not (4.6%).
Multivariate models
Antidepressants
Women presented a cumulative incidence of AD use almost two and a half times higher 
than men in the studied period. Using the younger age group (22–34 years) as a reference, 
there was an increase of about 50% in the incidence in the 45–54 years age group, and a 
decrease by half in the group aged over 55, although the p-value reached a borderline level of 
significance (p = 0.06). The incidence of AD use for individuals with higher education, even 
if incomplete, was more than two times that for individuals without any higher education. 
Individuals suspected to have CMD (GHQ ≥ 3) had an AD use 34% higher than those with 
no disorder, but with a borderline p-value (0.08). The complaint of tiredness presented a 
dose-response relationship with the use of these psychotropic medicines (Table 4).
Benzodiazepines
Women presented a cumulative incidence 58% higher than men in the studied period. 
Individuals self-classified as brown, black, and indigenous individuals were shown to have 
higher risk of being a BDZ incident user. The incidence of these medicines among widowers was 
1999 and 2001: two-weeks prevalence; 2006-2007 and 2012: one-week prevalence
Figure 1. Prevalence of antidepressants and benzodiazepines in the four cohort waves (1999, 2001, 
2006-07, 2012). Pró-Saúde Study, Brazil.
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twice as high as that observed for married individuals. There was an increase in the incidence 
of BDZ use as the participants’ perception of their health status worsened. There was a 34% 
higher incidence of BDZ use among those with a GHQ-12 score compatible with CMD, as well 
as a direct dose-response pattern for the waking up during the sleep cycle variable (Table 4).
DISCUSSION
In the study population, an increase in both AD and BDZ use was observed between 1999 and 
2012, although this increase has been proportionally higher for the first drug (Figure 1). This 
pattern is consistent with what has been observed in other countries, having as probable 
causes the introduction of new AD pharmacological classes1, the reduced side-effects of the 
most recent AD1,2, and an expansion in the spectrum of AD indications3,18–20.
Table 2. Distribution of antidepressants and benzodiazepines users according to class and medications 
(1999, 2001, 2006-2007, 2012). Pró-Saúde Study, Brazil.
Classes/medications
Phase 1 
N (%)
Phase 2 
N (%)
Phase 3 
N (%)
Phase 4 
N (%)
Antidepressants
Non-selective monoamine inhibitors 35 (60.3) 26 (36.7) 31 (22.2) 24 (15.2)
 Amitriptyline 17 (29.3) 12 (17.0) 14 (10.0) 12 (7.6)
 Amitriptyline + chlordiazepoxide 4 (6.9) 6 (8.5) 5 (3.6) 0.0
 Clomipramine 2 (3.4) 3 (4.2) 6 (4.3) 3 (1.9)
 Imipramine 9 (15.5) 4 (5.6) 1 (0.7) 4 (2.5)
 Nortriptyline 3 (5.2) 1 (1.4) 5 (3.6) 5 (3.2)
Selective Serotonin Reuptake Inhibitors 17 (29.31) 32 (45.1) 87 (62.7) 106 (67.6)
 Citalopram 1 (1.7) 0.0 3 (2.2) 10 (6.4)
 Escitalopram 0.0 0.0 4 (2.9) 12 (7.6)
 Fluoxetine 10 (17.2) 17 (24.0) 51 (36.7) 47 (30.0)
 Paroxetine 3 (5.2) 11 (15.5) 13 (9.4) 16 (10.2)
 Sertraline 3 (5.2) 4 (5.6) 16 (11.5) 21 (13.4)
Others 3 (5.1) 3 (4.2) 16 (11.5) 22 (13.9)
 Bupropion 0.0 3 (4.2) 4 (2.9) 3 (1.9)
 Desvenlafaxine 0.0 0.0 0.0 1 (0.6)
 Duloxetine 0.0 0.0 2 (1.4) 6 (3.8)
 Mirtazapine 1 (1.7) 0.0 1 (0.7) 0.0
 Trazodone 1 (1.7) 0.0 4 (2.9) 4 (2.5)
 Venlafaxine 1 (1.7) 0.0 5 (3.6) 8 (5.1)
Only the class declared 4 (6.9) 10 (14.1) 7 (5.0) 6 (3.8)
Benzodiazepines
 Alprazolam 8 (4.2) 24 (12.4) 28 (12.2) 21 (10.5)
 Bromazepam 83 (43.7) 66 (34.0) 43 (18.8) 24 (12.0)
 Clobazam 2 (1.0) 0.0 2 (0.9) 3 (1.5)
 Clonazepam 9 (4.7) 21 (10.8) 82 (36.0) 101 (50.5)
 Clorazepate dipotassium 1 (0.5) 0.0 0.0 0.0
 Cloxazolam 16 (8.4) 23 (11.9) 15 (6.5) 15 (7.5)
 Diazepam 41(21.6) 38 (19.6) 44 (19.2) 24 (12.0)
 Flunitrazepam 0.0 10 (0.5) 5 (2.2) 2 (1.0)
 Flurazepam 3 (1.6) 2 (1.0) 1 (0.4) 2 (1.0)
 Lorazepam 4 (2.1) 6 (3.1) 2 (0.9) 2 (1.0)
 Midazolam 3 (1.6) 4 (2.1) 3 (1.3) 2 (1.0)
 Nitrazepam 0.0 1 (0.5) 0.0 0.0
Only the class declared 23 (12.1) 13 (6.7) 10 (4.4) 8 (4.0)
One individual may be in more than one drug pharmacological class.
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Table 3. Cumulative incidence over 8 years (1999-2007) of antidepressant and benzodiazepine use 
stratified according to sociodemographic variables and self-reported health condition. Pró-Saúde 
Study, Brazil.
 
Incidence of AD (%)  
(95%CI)
p-value
Incidence of BDZ (%) 
(95%CI)
p-value
Total 4.9 (4.2–5.7)  8.3 (7.3–9.3)  
Sex  
 Men 2.1 (1.3–2.9)
< 0.001
5.3 (4.1–6.6)
< 0.001
 Women 7.2 (6.0–8.4) 10.6 (9.1–12.2)
Age
 22–34 4.9 (3.4–6.4)
0.20
6.0 (4.4–7.7)
< 0.001
 35–44 5.0 (3.9–6.2) 8.2 (6.7–9.7)
 45–54 5.7 (3.9–7.5) 10.0 (7.6–12.3)
 55 or more 1.7 (0.0–3.7) 13.3 (8.4–18.7)
Marital status
 Married or living together 4.2 (3.3–5.1)
0.08
7.2 (6.2–8.4)
< 0.001
 Separated or divorced 6.8 (4.5–9.2) 10.8 (7.8–13.8)
 Widower 7.4 (1.7–13.1) 22.2 (13.1–31.3)
 Single 5.5 (3.7–7.3) 8.2 (6.0–10.5)
Race/color     
 Black 4.1 (2.3–5.9)
0.27
11.3 (8.4–14.2)
0.02
 Brown 4.2 (2.9–5.4) 7.2 (5.5–8.8)
 White 5.9 (4.7–7.1) 8.0 (6.6–9.4)
 Asian 3.8 (0.0–8.9) 7.8 (0.4–15.3)
 Indigenous 3.1 (0.0–9.2) 18.7 (5.0–32.5)
Education level     
 Some elementary school 2.8 (0.6–5.1)
0.03
9.9 (5.8–14.0)
0.50
 Elementary school 2.5 (0.5–4.6) 6.5 (3.3–9.7)
 Some high school 2.8 (0.9–4.7) 8.1 (4.8–11.4)
 High school 4.5 (2.9–6.0) 9.0 (6.9–11.2)
 Some college 6.7 (4.3–9.1) 7.4 (4.8–9.9)
 College 6.1 (4.5–7.8) 7.3 (5.5–9.1)
 Graduate  6.2 (3.5-8.8)  10.3 (7.0-13.7)
Workplace
 UERJ Campus1 4.1 (3.1–5.1)
0.04
6.9 (5.6–8.2)
0.01
 HUPE Hospital2 5.7 (4.6–6.9) 9.6 (8.1–11.1)
Income equivalence (minimum wages)     
 Up to 3 3.5 (1.3–5.8)
0.45
8.7 (5.1–12.3)
0.96 3 to 6 4.8 (3.3–6.3) 8.1 (6.2–10.1)
 >6 5.3 (4.3–6.3) 8.2 (7.0–9.5)
Health insurance users     
 Yes 5.6 (4.5–6.7)
0.10
8.7 (7.4–10.1)
0.32
 No 4.2 (3.2–5.3) 7.7 (6.3–9.2)
Alcohol consumption
Yes 4.2 (3.2–5.2)
0.07
7.3 (6.0–8.6)
0.07
No 5.7 (4.4–6.9) 9.2 (7.6–10.8)
Frequency of alcohol consumption (2 weeks)
Every day 1.7 (0.0–5.0)
0.41
3.6 (0.0–8.6)
0.67
10 to 13 days 5.3 (0.0–11.3) 9.2 (1.4–17.0)
6 to 9 days 7.2 (2.6–11.7) 8.1 (3.3–13.0)
2 to 5 days 3.9 (2.6–5.2) 6.9 (5.2–8.7)
1 single day 4.2 (2.5–6.0) 8.3 (5.9–10.7)
(Continue)
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Incidence of AD (%)  
(95%CI)
p-value
Incidence of BDZ (%) 
(95%CI)
p-value
Amount of alcohol consumed per day (2 weeks)
1 standard unit 4.6 (2.7–6.5)
0.98
7.2 (4.8–9.5)
0.009
2 to 4 standard unit 4.1 (2.6–5.6) 5.8 (4.0–7.6)
5 to 7 standard unit 4.1 (1.6–6.6) 13.0 (8.7–17.3)
8 a 10 standard unit 3.8 (0.1–7.4) 7.9 (2.6–13.2)
More than 10 standard unit 5.0 (0.7–9.4) 6.5 (1.4–11.6)
Health condition     
 Very good 3.6 (2.3–4.8)
< 0.001
5.1 (3.6–6.5)
< 0.001
 Good 4.7 (3.7–5.7) 7.9 (6.6–9.2)
 Regular 8.0 (5.6–10.5) 14.2 (11.1–17.5)
 Bad 8.3 (0.0–17.5) 22.8 (8.7–37.0)
Current health condition     
 Better than 12 months ago 5.1 (3.3–6.9)
0.004
12.1 (9.4–14.9)
< 0.001 Same as 12 months ago 4.3 (3.5–5.2) 6.7 (5.6–7.8)
 Worse than 12 months ago 8.4 (5.6–11.2) 11.5 (8.1–14.9)
GHQ-12 (Positive ≥ 3)     
 Negative 3.7 (2.9–4.5)
< 0.001
6.3 (5.3–7.4)
< 0.001
 Positive 8.0 (6.2–9.7) 12.7 (10.5–15.0)
Difficulty falling asleep     
 Always 10.6 (5.3–15.9)
< 0.001
21.7 (13.8–29.6)
< 0.001
 Almost Always 4.6 (1.8–7.3) 21.8 (16.1–27.5)
 Sometimes 6.2 (4.4–8.0) 9.4 (7.2–11.2)
 Rarely 4.6 (3.0–6.2) 6.9 (5.0–8.9)
 Never 3.9 (2.8–5.0) 5.0 (3.8–6.2)
Wake up during sleep cycle     
 Always 11.5 (5.4–17.7)
< 0.001
19.5 (11.1–27.9)
< 0.001
 Almost Always 3.4 (1.1–5.7) 19.2 (14.0–24.4)
 Sometimes 7.5 (5.5–9.5) 9.9 (7.6–12.3)
 Rarely 3.8 (2.4–5.3) 7.5 (5.5–9.5)
 Never 4.0 (2.9–5.0) 5.1 (3.5–6.4)
Tiredness for no apparent reason     
 Always 13.9 (8.0–19.7)
< 0.001
20.0 (12.8–27.2)
< 0.001
 Almost Always 9.0 (5.8–12.2) 17.0 (12.7–21.3)
 Sometimes 6.2 (4.6–7.9) 9.8 (7.7–11.8)
 Rarely 2.8 (14.5–4.2) 4.8 (3.0–6.6)
 Never 3.0 (2.0–4.0) 5.2 (3.9–6.4)
1 Universidade Estadual do Rio de Janeiro
2 Hospital University Pedro Ernesto
Table 3. Cumulative incidence over 8 years (1999-2007) of antidepressant and benzodiazepine use 
stratified according to sociodemographic variables and self-reported health condition. Pró-Saúde 
Study, Brazil. (Continuation)
This result partially confirms our initial hypothesis, as there was an increase in the use of 
AD, but not accompanied by a decrease in the BDZ use, but by more subtle increases in 
prevalence. That is, there was no substitution of BDZ by AD, but a possible association of 
both pharmacological classes to treat mental health disorders in some individuals21.
Paulose-Ram et al.22 also reported an increase in the prevalence of AD (2.5%, 1988–1994 versus 
8.1% 1999–2002) and BDZ use (3.5%, 1988–1994 versus 3.8%, 1999–2002) in the United States. 
However, a 1994 UK study found a reduction in the use of BDZ over time23. This reduced 
use of BDZ was also reported by other authors9.
A characteristic of the SSRI therapeutic approach is the recommendation of continuous 
and long-term treatment that may continue for up to 6 months or more after the symptoms 
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disappear. It is possible the use of AD in our sample was continuous, while for BDZ it was 
more short-term and episodic (to deal with anxiety and insomnia episodes).
In this study, SSRI were the most used AD; the proportion of their users nearly doubled 
from 1999 to 2012, agreeing with many studies14,24,25.
Table 4. Poisson regression models for cumulative incidence of the antidepressants and benzodiazepines 
use. Pró-Saúde Study, Brazil.
Variable
Antidepressants  Benzodiazepines
RR (95%CI) p-value RR (95%CI) p-value
Sex
 Men 1
< 0.001
1
0.001
 Women 2.66 (1.75–4.04) 1.58 (1.3–2.1)
Age     
 22–34 1 NI NI
 35–44 1.15 (0.78–1.70) 0.47 NI NI
 45–54 1.54 (1.0–2.44) 0.062 NI NI
 55 or more 0.53 (0.16–1.77) 0.305 NI NI
Marital status    
 Married or living together NI NI 1
 Separated or divorced NI NI 1.20 (0.86–1.68) 0.28
 Widower NI NI 2.15 (1.34–3.47) 0.002
 Single NI NI 1.03 (0.82–1.55) 0.46
Race/Color     
 Brown NI NI 1
 Black NI NI 1.47 (1.03–2.09) 0.03
 White NI NI 1.26 (0.93–1.71) 0.14
 Asian NI NI 1.25 (0.47–3.27) 0.65
 Indigenous NI NI 3.15 (1.42–6.97) 0.005
Education level     
 Some elementary school 1 NI NI
 Elementary school 0.99 (0.32–3.03) 0.98 NI NI
 Some high school 0.99 (0.34–2.84) 0.98 NI NI
 High school 1.7 (0.69–4.18) 0.25 NI NI
 Some college/ graduate 2.35 (0.98–5.62) 0.05 NI NI
Health condition     
 Very good NI NI 1
 Good NI NI 1.4 (0.98–2.00) 0.06
 Regular/Bad NI NI 1.81 (1.2–2.72) 0.005
GHQ-12 (Positive ≥ 3)     
 Negative 1
0.08
1
 Positive 1.34 (0.96–1.88) 1.34 (1.05–1.79) 0.03
Wake up during sleep cycle     
 Never NI NI 1
 Rarely NI NI 1.23 (0.85–1.77) 0.27
 Sometimes NI NI 1.45 (1.01–2.07) 0.04
 Almost Always/Always NI NI 2.71 (1.86–3.94) < 0.001
Tiredness for no apparent reason     
 Never 1 NI NI
 Rarely 0.84 (0.47–1.50) 0.56 NI NI
 Sometimes 1.73 (1.11–2.70) 0.015 NI NI
 Almost Always 2.02 (1.20–3.42) 0.008 NI NI
 Always 3.2 (1.82–5.66) < 0.001 NI NI
NI – Not included in the final regression model since it presented a p-value > 0.10.
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With the increase in SSRI use, there was a decrease in the use of other antidepressants, 
especially the TCA (mostly amitriptyline). The proportion of TCA users among AD users 
decreased by 75% between 1999 and 2012. This pattern agreed with other authors. In the 
US a reduction in the TCA use was observed, from 47% in 1987 to 2.1% by 20011. In Spain, 
in 2001–02, the frequency of SSRI use was 59.5%, and of TCA use was 25.5% among AD 
users5. In the US, an increase in the prevalence of SSRI use was also observed; in 1999, the 
prevalence of SSRI use was 4.3%, increasing to 8.5% in 201225. In São Paulo, the prevalence 
of SSRI use was 2.17%, and of TCA was 1.26% in 2005–200711, while in Chile the prevalence 
of SSRI use was 2.0% and TCA use was 1.8% in 1996–984.
When examining the use of both psychotropic medicines, the incidence of BDZ use between 
1999 and 2007 was twice as high as that for AD. In a longitudinal study conducted in France 
with less follow-up time than this study (1996–2001), it was found 2.3% of new AD users, 
2.8% anxiolytics, and 2.3% hypnotics26.
In this study, the first time an individual used AD or BDZ was not assessed, but the use that 
started (or restarted) during follow-up among those who did not use psychotropic medication 
at baseline was assessed. Since the assessment of incidence excluded AD and BDZ users at 
baseline, there may have been a higher chance of detecting the beginning or the return to BDZ 
use (medication that has a more cyclic or episodic use) than the beginning or return to AD use 
(a medication that tends to have a more prolonged and continuous use). This fact may have 
contributed to the higher increase in the found AD use compared with BDZ use in our follow-up.
Being a BDZ user at baseline increased the risk of the individual of starting AD use. The 
data are not surprising, given the evidence that primary care initiates the treatment of some 
mental disorders with BDZ before referring the individuals to specialists3. The literature 
reports that the use of BDZ to treat depression is common and that this use may continue 
even after the introduction of AD3. The use of AD was also found by Takeshima et al.27 to 
be a predictor not only for the initial use of BDZ but also as a predictor of prolonged used.
Cumulative incidence in the period from 1999 to 2006–07 was higher among women, both 
for AD and BDZ as others have observed24,26. Anxiety disorders and depression have been 
consistently described as being more frequent among women7,14, who also have a higher 
tendency to seek medical care7; besides, new indications for AD use encompasses ailments 
that are specifically or primarily suffered by women, such as premenstrual syndrome, 
premenstrual dysphoric disorder, eating disorders, fibromyalgia, and headaches18,19,20,24.
There was an increase in the incidence of BDZ with age. However, in the AD case, the very oldest 
age group presented a significant reduction in incidence. This decrease in our sample may be due 
to a healthy worker effect28; the small size of this age group may have also affected the results.
Increased education level was associated with the incidence of AD use, but not with BDZ 
use. Some hypotheses may explain this result. Individuals with a greater education level may 
describe their condition more clearly, leading to a more adequate treatment. These individuals 
may seek help from a psychiatrist rather than a general practitioner29; furthermore, in general 
they have higher incomes, allowing them to afford the AD cost, usually higher than the BDZ cost.
The incidence of BDZ use was higher among individuals that classified their health status 
as poor, consistently with the fact that chronic health conditions, both physical and mental, 
increase the search for professional help and the prescription of psychotropic medicine26,30. In 
the bivariate analysis, AD was also shown to be associated with the worst health perception. 
The fact that this association was not maintained in the multivariate analysis may be due 
to less statistical power in the analysis of these medicines, due to lower incidence when 
compared with BDZ. The incidence of BDZ use was also higher among people who reported 
having trouble falling and remaining asleep. This result is expected considering that BDZ 
is broadly prescribed worldwide for such conditions27. However, complaints of tiredness in 
the baseline were associated with higher AD use, which can be explained because of this 
complaint association with depressive disorders.
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This study reported the cumulative incidence of AD and BDZ use over a 13-year period, 
results that are unprecedented. Among the study limitations, the fact of not covering the 
medication use for the entire follow-up may have non-differentially misclassified some 
participants, therefore producing an underestimation of the incidence estimates. On the 
other hand, this restriction may have minimized the memory bias.
Contrary to our hypothesis and to the findings reported by other studies, this analysis 
did not corroborate the previous impression that the use of BDZ was being gradually 
replaced by the use of AD for many individuals. These results did not show an increase in 
the incidence of AD use followed by a decrease in the incidence of BDZ use. The reasons for 
such phenomenon are not clear. It is likely that AD is being added to the use of BDZ, and 
not just substituting the latter in the study population. It is imperative that AD and BDZ 
prescriptions are in agreement with the current treatment guidelines, especially considering 
the rational use of psychotropic medications.
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